Parvari R, Lei K J, Szonyi L, Narkis G, Moses S, Chou J Y
Genetics Institute Soroka Medical Center, Beer Sheva, Israel.
Eur J Hum Genet. 1997 Jul-Aug;5(4):191-5.
Glycogen storage disease type 1a (von Gierke disease, GSD-1A) is caused by the deficiency of microsomal glucose-6-phosphatase (G6Pase) activity which catalyzes the final common step of glycogenolysis and gluconeogenesis. The cloning of the G6Pase cDNA and characterization of the human G6Pase gene enabled the identification of the mutations causing GSD-1a. This, in turn, allows the development of non-invasive DNA-based diagnosis that provides reliable carrier testing and prenatal diagnosis. Here we report on two new mutations E110Q and D38V causing GSD-1a in two Hungarian patients. The analyses of these mutations by site-directed mutagenesis followed by transient expression assays demonstrated that E110Q retains 17% of G6Pase enzymatic activity while the D38V abolishes the enzymatic activity. The patient with the E110Q has G222R as his other mutation. G222R was also shown to preserve about 4% of the G6Pase enzymatic activity. Nevertheless, the patient presented with the classical severe symptomatology of the GSD-1a.
1a型糖原贮积病(冯·吉尔克病,GSD - 1A)是由微粒体葡萄糖 - 6 - 磷酸酶(G6Pase)活性缺乏引起的,该酶催化糖原分解和糖异生的最终共同步骤。G6Pase cDNA的克隆和人类G6Pase基因的特征分析使得能够鉴定出导致GSD - 1a的突变。这反过来又促进了基于DNA的非侵入性诊断方法的发展,这种方法可提供可靠的携带者检测和产前诊断。在此,我们报告在两名匈牙利患者中发现导致GSD - 1a的两个新突变E110Q和D38V。通过定点诱变随后进行瞬时表达分析对这些突变进行分析表明,E110Q保留了17%的G6Pase酶活性,而D38V则消除了酶活性。携带E110Q突变的患者还有另一个突变G222R。G222R也被证明保留了约4%的G6Pase酶活性。然而,该患者仍表现出GSD - 1a典型的严重症状。